231 related articles for article (PubMed ID: 28188713)
1. [Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease].
Molina-Sáenz MM; Villa-Arango AM; Cardona-Villa R
Rev Alerg Mex; 2017; 64(1):52-65. PubMed ID: 28188713
[TBL] [Abstract][Full Text] [Related]
2. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
3. Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy.
Moreno V; Alvariño M; Rodríguez F; Roger A; Peña-Arellano MI; Lleonart R; Pagán JA; Navarro JA; Navarro LA; Vidal C; Ponte-Tellechea A; Gómez-Fernández MC; Madariaga-Goirigolzarri B; Asturias JA; Hernández-Fernandez de Rojas D
Immunotherapy; 2016; 8(3):265-77. PubMed ID: 26757045
[TBL] [Abstract][Full Text] [Related]
4. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
[TBL] [Abstract][Full Text] [Related]
5. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
6. [House dust mite allergy: myths and realities].
Bouton C; Ducommun J
Rev Med Suisse; 2009 Apr; 5(199):832-6. PubMed ID: 19441749
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
[TBL] [Abstract][Full Text] [Related]
8. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
Cardona R; Lopez E; Beltrán J; Sánchez J
Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
[TBL] [Abstract][Full Text] [Related]
9. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
[TBL] [Abstract][Full Text] [Related]
11. Mite immunotherapy.
Fernández-Caldas E; Iraola V; Boquete M; Nieto A; Casanovas M
Curr Allergy Asthma Rep; 2006 Sep; 6(5):413-9. PubMed ID: 16899204
[TBL] [Abstract][Full Text] [Related]
12. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
[TBL] [Abstract][Full Text] [Related]
13. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis].
Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357
[No Abstract] [Full Text] [Related]
14. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis.
Zhou J; Chen S; Song Z
Allergy Asthma Proc; 2021 Mar; 42(2):e47-e54. PubMed ID: 33685566
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma.
Hernández Fernández de Rojas D; Antépara Ercoreca I; Ponte Tellechea A; Ibáñez Echevarría E; Jáuregui Presa I; Gamboa Setién P; Asturias JA; Landeta Manzano A; Madariaga Goirigolzarri B
Immunotherapy; 2015; 7(2):89-99. PubMed ID: 25659029
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis].
Zhou L; Wang J; Chen Y; Luo R; Tao J; Nie M; Liu B; Li Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Oct; 26(20):913-6. PubMed ID: 23272490
[TBL] [Abstract][Full Text] [Related]
18. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
[TBL] [Abstract][Full Text] [Related]
19. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
[TBL] [Abstract][Full Text] [Related]
20. Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?
Rondon C; Sánchez-Borges M; Cupello ER; Fabiano F; Capriles-Hulett A
Allergol Immunopathol (Madr); 2021; 49(2):31-39. PubMed ID: 33641291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]